Lactoferrin during lactation protects the immature hypoxic-ischemic rat brain

Annals of Clinical and Translational Neurology

Volumn 1, Issue 12, 2014, Pages 955-967

  van de Looij, Yohan ^a,b   Ginet, Vanessa ^a   Chatagner, Alexandra ^a   Toulotte, Audrey ^a   Somm, Emmanuel ^a   Hüppi, Petra S ^a   Sizonenko, Stéphane V ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CASPASE 3; CYTOKINE; GLUTAMINE; INTERLEUKIN 6; LACTOFERRIN; N ACETYLASPARTYLGLUTAMIC ACID; PROTEIN BAD; TAURINE; TUMOR NECROSIS FACTOR;

ACUTE PHASE RESPONSE; AKT SIGNALING; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BOVINE; BRAIN CORTEX; BRAIN INJURY; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; CORPUS CALLOSUM; DIET SUPPLEMENTATION; FEMALE; FRACTIONAL ANISOTROPY; GENETIC TRANSCRIPTION; HYPOXIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOBLOTTING; LACTATION; MALE; MENTAL DISEASE; MILK; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTNATAL CARE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPECTROSCOPY; WHITE MATTER;

EID: 85016576694     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.138     Document Type: Article

References (81)

1. Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr 2010;156(2 suppl):S3–S7.
2. Isaacs EB, Fischl BR, Quinn BT, et al. Impact of breast milk on intelligence quotient, brain size, and white matter development. Pediatr Res 2010;67:357–362.
3. Metz-Boutigue MH, Jolles J, Mazurier J, et al. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 1984;17:659–676.
4. Belizy S, Nasarova IN, Procof'ev VN, et al. Changes in antioxidative properties of lactoferrin from women's milk during deamidation. Biochemistry 2001;66:576–580.
5. Garcia-Montoya IA, Cendon TS, Arevalo-Gallegos S, et al. Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta 2012;1820:226–236.
6. Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol 2012;90:252–268.
7. Maneva A, Taleva B, Maneva L. Lactoferrin-protector against oxidative stress and regulator of glycolysis in human erythrocytes. Z Naturforsch [C] 2003;58:256–262.
8. Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 2004;17:189–196.
9. Raghuveer TS, McGuire EM, Martin SM, et al. Lactoferrin in the preterm infants' diet attenuates iron-induced oxidation products. Pediatr Res 2002;52:964–972.
10. Nagasawa T, Kiyosawa I, Kuwahara K. Amounts of lactoferrin in human colostrum and milk. J Dairy Sci 1972;55:1651–1659.
11. Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009;302:1421–1428.
12. Back SA, Luo NL, Borenstein NS, et al. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J Neurosci 2001;21:1302–1312.
13. Hasegawa A, Otsuki K, Sasaki Y, et al. Preventive effect of recombinant human lactoferrin in a rabbit preterm delivery model. Am J Obstet Gynecol 2005;192:1038–1043.
14. Mitsuhashi Y, Otsuki K, Yoda A, et al. Effect of lactoferrin on lipopolysaccharide (LPS) induced preterm delivery in mice. Acta Obstet Gynecol Scand 2000;79:355–358.
15. Paesano R, Pietropaoli M, Berlutti F, et al. Bovine lactoferrin in preventing preterm delivery associated with sterile inflammation. Biochem Cell Biol 2012;90:468–475.
16. Somm E, Larvaron P, van de Looij Y, et al. Protective effects of maternal nutritional supplementation with lactoferrin on growth and brain metabolism. Pediatr Res 2014;75:51–61.
17. Legrand D, Pierce A, Elass E, et al. Lactoferrin structure and functions. Adv Exp Med Biol 2008;606:163–194.
18. Suzuki YA, Lopez V, Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 2005;62:2560–2575.
19. Ji B, Maeda J, Higuchi M, et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006;78:851–855.
20. Kamalinia G, Khodagholi F, Atyabi F, et al. Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies. Mol Pharm 2013;10:4418–4431.
21. Liu Z, Jiang M, Kang T, et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 2013;34:3870–3881.
22. Qian ZM, Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Brain Res Rev 1998;27:257–267.
23. Fillebeen C, Dexter D, Mitchell V, et al. Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. Adv Exp Med Biol 1998;443:293–300.
24. Kawamata T, Tooyama I, Yamada T, et al. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol 1993;142:1574–1585.
25. Wang L, Sato H, Zhao S, et al. Deposition of lactoferrin in fibrillar-type senile plaques in the brains of transgenic mouse models of Alzheimer's disease. Neurosci Lett 2010;13:164–167.
26. Rousseau E, Michel PP, Hirsch EC. The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis. Mol Pharmacol 2013;84:888–898.
27. Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol 2009;8:110–124.
28. Sizonenko SV, Camm EJ, Garbow JR, et al. Developmental changes and injury induced disruption of the radial organization of the cortex in the immature rat brain revealed by in vivo diffusion tensor MRI. Cereb Cortex 2007;17:2609–2617.
29. Sizonenko SV, Kiss JZ, Inder T, et al. Distinctive neuropathologic alterations in the deep layers of the parietal cortex after moderate ischemic-hypoxic injury in the P3 immature rat brain. Pediatr Res 2005;57:865–872.
30. Sizonenko SV, Sirimanne E, Mayall Y, et al. Selective cortical alteration after hypoxic-ischemic injury in the very immature rat brain. Pediatr Res 2003;54:263–269.
31. van de Looij Y, Chatagner A, Huppi PS, et al. Longitudinal MR assessment of hypoxic ischemic injury in the immature rat brain. Magn Reson Med 2011;65:305–312.
32. van de Looij Y, Mauconduit F, Beaumont M, et al. Diffusion tensor imaging of diffuse axonal injury in a rat brain trauma model. NMR Biomed 2012;25:93–103.
33. Obenaus A, Ashwal S. Magnetic resonance imaging in cerebral ischemia: focus on neonates. Neuropharmacology 2008;55:271–280.
34. Favrais G, van de Looij Y, Fleiss B, et al. Systemic inflammation disrupts the developmental program of white matter. Ann Neurol 2011;70:550–565.
35. van de Looij Y, Lodygensky GA, Dean J, et al. High-field diffusion tensor imaging characterization of cerebral white matter injury in lipopolysaccharide-exposed fetal sheep. Pediatr Res 2012;72:285–292.
36. van Velthoven CT, van de Looij Y, Kavelaars A, et al. Mesenchymal stem cells restore cortical rewiring after neonatal ischemia in mice. Ann Neurol 2012;71:785–796.
37. Marques JP, Maddage R, Mlynarik V, et al. On the origin of the MR image phase contrast: an in vivo MR microscopy study of the rat brain at 14.1 T. NeuroImage 2009;46:345–352.
38. Lodygensky GA, Marques JP, Maddage R, et al. In vivo assessment of myelination by phase imaging at high magnetic field. NeuroImage 2012;59:1979–1987.
39. Wharton S, Bowtell R. Effects of white matter microstructure on phase and susceptibility maps. Magn Reson Med 2014; (doi 10.1002/mrm.25189).
40. Manzoni P, Meyer M, Stolfi I, et al. Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. Early Human Dev 2014;90(suppl 1):S60–S65.
41. Ochoa TJ, Pezo A, Cruz K, et al. Clinical studies of lactoferrin in children. Biochem Cell Biol 2012;90:457–467.
42. Paesano R, Pacifici E, Benedetti S, et al. Safety and efficacy of lactoferrin versus ferrous sulphate in curing iron deficiency and iron deficiency anaemia in hereditary thrombophilia pregnant women: an interventional study. Biometals 2014;27:999–1006.
43. van de Looij Y, Chatagner A, Quairiaux C, et al. Multi-modal assessment of long-term erythropoietin treatment after neonatal hypoxic-ischemic injury in rat brain. PLoS One 2014;9:e95643.
44. Gruetter R, Tkac I. Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med 2000;43:319–323.
45. van de Looij Y, Kunz N, Huppi P, et al. Diffusion tensor echo planar imaging using surface coil transceiver with a semiadiabatic RF pulse sequence at 14.1T. Magn Reson Med 2011;65:732–737.
46. Hasan KM, Parker DL, Alexander AL. Comparison of gradient encoding schemes for diffusion-tensor MRI. J Magn Reson Imaging 2001;13:769–780.
47. Rivière D, Régis J, Cointepas Y, et al. A freely available Anatomist/BrainVISA package for structural morphometry of the cortical sulci. NeuroImage 2003;19:934.
48. Brehmer F, Bendix I, Prager S, et al. Interaction of inflammation and hyperoxia in a rat model of neonatal white matter damage. PLoS One 2012;7:e49023.
49. Sizonenko SV, Camm EJ, Dayer A, et al. Glial responses to neonatal hypoxic-ischemic injury in the rat cerebral cortex. Int J Dev Neurosci 2008;26:37–45.
50. Kamemori N, Takeuchi T, Sugiyama A, et al. Trans-endothelial and trans-epithelial transfer of lactoferrin into the brain through BBB and BCSFB in adult rats. J Vet Med Sci 2008;70:313–315.
51. Lei H, Berthet C, Hirt L, et al. Evolution of the neurochemical profile after transient focal cerebral ischemia in the mouse brain. J Cereb Blood Flow Metab 2009;29:811–819.
52. Neale JH, Olszewski RT, Zuo D, et al. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem 2011;118:490–498.
53. Wroblewska B, Santi MR, Neale JH. N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 1998;24:172–179.
54. Wroblewska B, Wroblewski JT, Pshenichkin S, et al. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 1997;69:174–181.
55. Dean JM, McClendon E, Hansen K, et al. Prenatal cerebral ischemia disrupts MRI-defined cortical microstructure through disturbances in neuronal arborization. Sci Transl Med 2013;5:168ra7.
56. Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002;22:455–463.
57. Barazany D, Basser PJ, Assaf Y. In vivo measurement of axon diameter distribution in the corpus callosum of rat brain. Brain 2009;132(Pt 5):1210–1220.
58. Chatterton DE, Nguyen DN, Bering SB, et al. Anti-inflammatory mechanisms of bioactive milk proteins in the intestine of newborns. Int J Biochem Cell Biol 2013;45:1730–1747.
59. Lingappan K, Arunachalam A, Pammi M. Lactoferrin and the newborn: current perspectives. Expert Rev Anti Infect Ther 2013;11:695–707.
60. Hagberg H, Gilland E, Bona E, et al. Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats. Pediatr Res 1996 Oct;40:603–609.
61. Li SJ, Liu W, Wang JL, et al. The role of TNF-alpha, IL-6, IL-10, and GDNF in neuronal apoptosis in neonatal rat with hypoxic-ischemic encephalopathy. Eur Rev Med Pharmacol Sci 2014;18:905–909.
62. Szaflarski J, Burtrum D, Silverstein FS. Cerebral hypoxia-ischemia stimulates cytokine gene expression in perinatal rats. Stroke 1995;26:1093–1100.
63. Yoon BH, Romero R, Kim CJ, et al. High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia. Am J Obstet Gynecol 1997;177:406–411.
64. Lambertsen KL, Clausen BH, Babcock AA, et al. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci 2009;29:1319–1330.
65. Suzuki S, Tanaka K, Suzuki N. Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects. J Cereb Blood Flow Metab 2009;29:464–479.
66. Leonardo CC, Pennypacker KR. Neuroinflammation and MMPs: potential therapeutic targets in neonatal hypoxic-ischemic injury. J Neuroinflammation 2009;6:13.
67. Carty ML, Wixey JA, Reinebrant HE, et al. Ibuprofen inhibits neuroinflammation and attenuates white matter damage following hypoxia-ischemia in the immature rodent brain. Brain Res 2011;1402:9–19.
68. Martin D, Chinookoswong N, Miller G. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol 1994;130:362–367.
69. Wixey JA, Reinebrant HE, Spencer SJ, et al. Efficacy of post-insult minocycline administration to alter long-term hypoxia-ischemia-induced damage to the serotonergic system in the immature rat brain. Neuroscience 2011;182:184–192.
70. Nakajima W, Ishida A, Lange MS, et al. Apoptosis has a prolonged role in the neurodegeneration after hypoxic ischemia in the newborn rat. J Neurosci 2000;20:7994–8004.
71. Northington FJ, Ferriero DM, Graham EM, et al. Early neurodegeneration after hypoxia-ischemia in neonatal rat is necrosis while delayed neuronal death is Apoptosis. Neurobiol Dis 2001;8:207–219.
72. Stadlin A, James A, Fiscus R, et al. Development of a postnatal 3-day-old rat model of mild hypoxic-ischemic brain injury. Brain Res 2003;993:101–110.
73. Zhu C, Wang X, Xu F, et al. The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ 2005;12:162–176.
74. Wang Y, Cao M, Liu A, et al. Changes of inflammatory cytokines and neurotrophins emphasized their roles in hypoxic-ischemic brain damage. Int J Neurosci 2013;123:191–195.
75. Haynes RL, Billiards SS, Borenstein NS, et al. Diffuse axonal injury in periventricular leukomalacia as determined by apoptotic marker fractin. Pediatr Res 2008;63:656–661.
76. Schulz R, Vogel T, Mashima T, et al. Involvement of Fractin in TGF-beta-induced apoptosis in oligodendroglial progenitor cells. Glia 2009;57:1619–1629.
77. Luo HR, Hattori H, Hossain MA, et al. Akt as a mediator of cell death. Proc Natl Acad Sci USA 2003;100:11712–11717.
78. Mullonkal CJ, Toledo-Pereyra LH. Akt in ischemia and reperfusion. J Invest Surg 2007;20:195–203.
79. van den Tweel ER, Kavelaars A, Lombardi MS, et al. Bilateral molecular changes in a neonatal rat model of unilateral hypoxic-ischemic brain damage. Pediatr Res 2006;59:434–439.
80. Ferriero DM. Neonatal brain injury. N Engl J Med 2004;351:1985–1995.
81. Vogel HJ. Lactoferrin, a bird's eye view. Biochem Cell Biol 2012;90:233–244.